Adalimumab is a biologic medication used to treat several inflammatory and autoimmune conditions, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. Its dosage and administration schedule depend on the condition being treated, the patient’s age, medical history, and response to therapy.
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces inflammation by targeting a protein involved in inflammatory processes. It is administered as a subcutaneous injection, meaning the medication is injected beneath the skin. The prescribed dose and frequency vary according to the medical condition, patient characteristics, and specific product instructions.
There is no single dosage schedule suitable for everyone. Some conditions require an initial loading dose followed by maintenance injections, while others use a regular schedule from the beginning. Patients should follow their healthcare professional’s instructions and avoid changing the dose independently.
Common factors influencing dosage include:
Medical condition: Rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, Crohn’s disease, and plaque psoriasis may have different dosing schedules.
Age and body weight: Pediatric dosing for certain conditions may depend on body weight and age, whereas adult regimens vary by indication.
Treatment response: Healthcare professionals evaluate symptom control and tolerability when assessing whether treatment should continue.
Other medications: Some patients receive adalimumab alongside other medicines, which can influence treatment planning and monitoring.
Adalimumab is commonly supplied in prefilled syringes or injection pens, depending on the product. Patients who administer it at home should receive appropriate training from a healthcare professional. Following the product-specific instructions helps support correct administration and reduces the risk of injection errors.
Before each injection, patients should check the medication’s appearance, expiration date, and packaging. The injection site should be selected according to the product instructions, and injection sites should generally be rotated. Adalimumab products usually require refrigeration and protection from light; storage conditions and permitted room-temperature periods vary by product.
Important administration and safety considerations include:
Injection technique: Use the prescribed device and follow the instructions supplied with the medication. Do not inject into skin that is bruised, tender, red, hard, or damaged.
Missed doses: Contact a healthcare professional or follow the specific product instructions for guidance. Do not double the next dose unless explicitly instructed.
Infection screening: Patients generally require evaluation for tuberculosis and other relevant infections before treatment. Hepatitis B screening may also be necessary.
Possible side effects: Injection-site reactions, headaches, and upper respiratory infections may occur. Seek prompt medical attention for signs of serious infection or an allergic reaction.
Vaccinations: Discuss vaccinations with a healthcare professional before treatment. Live vaccines are generally avoided during adalimumab therapy.
Ongoing monitoring: Report new symptoms, persistent fever, unusual bruising, or other concerning changes to the treating clinician.
The prescribed regimen should always be based on the specific condition and the official prescribing information for the product being used. Patients should not start, stop, or adjust adalimumab without consulting their healthcare professional.